Display options
Cite
Liu X, Feng M, Zheng G, et al. TCRP1 expression is associated with platinum sensitivity in human lung and ovarian cancer cells. Oncol Lett. 2016;13(3):1398-1405doi: 10.3892/ol.2016.5534.
Liu, X., Feng, M., Zheng, G., Gu, Y., Wang, C., & He, Z. (2017). TCRP1 expression is associated with platinum sensitivity in human lung and ovarian cancer cells. Oncology letters, 13(3), 1398-1405. https://doi.org/10.3892/ol.2016.5534
Liu, Xiaorong, et al. "TCRP1 expression is associated with platinum sensitivity in human lung and ovarian cancer cells." Oncology letters vol. 13,3 (2017): 1398-1405. doi: https://doi.org/10.3892/ol.2016.5534
Liu X, Feng M, Zheng G, Gu Y, Wang C, He Z. TCRP1 expression is associated with platinum sensitivity in human lung and ovarian cancer cells. Oncol Lett. 2017 Mar;13(3):1398-1405. doi: 10.3892/ol.2016.5534. Epub 2016 Dec 27. PMID: 28454268; PMCID: PMC5403207.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2017 Mar;13(3):1398-1405. doi: 10.3892/ol.2016.5534. Epub 2016 Dec 27.

TCRP1 expression is associated with platinum sensitivity in human lung and ovarian cancer cells.

Oncology letters

Xiaorong Liu, Meiling Feng, Guopei Zheng, Yixue Gu, Chengkun Wang, Zhimin He

Affiliations

  1. Affiliated Cancer Hospital and Cancer Research Institute, Guangzhou Medical University, Guangzhou, Guangdong 510095, P.R. China.
  2. Shenzhen Engineering Laboratory for High-throughput Gene Sequencing of Pathogens, Shenzhen Children's Hospital, Shenzhen, Guandong 518038, P.R. China.

PMID: 28454268 PMCID: PMC5403207 DOI: 10.3892/ol.2016.5534

Abstract

Platinum-based drugs, including cisplatin (DDP) and oxaliplatin (L-OHP), are among the most potent chemotherapy drugs, and are widely utilized for the treatment of human lung and ovarian cancer. However, certain patients do not respond to platinum-based agents, and even those who initially benefit from the treatment will eventually exhibit resistance to these drugs. Although certain factors have been investigated for their potential to predict platinum resistance, more effective predictors for the improved management of patients with lung and ovarian cancer are required. Tongue cancer resistance-associated protein 1 (TCRP1) is a newly identified gene, which was cloned from a multi-drug resistant cell line of tongue cancer. Previous data has shown that TCRP1 is able to mediate DDP resistance in human oral squamous cell carcinoma cells. However, the contribution of TCRP1 to the resistance of platinum agents in human lung and ovarian cancer cells remains to be elucidated. Our previous study showed that TCRP1 expression levels in samples of lung and ovarian cancer were significantly increased compared with normal controls. In the present study, it was demonstrated that TCRP1 contributed to the resistance to DDP and L-OHP in human lung and ovarian cancer cells. Knockdown of TCRP1 resensitized the cells to the platinum-based agents. The present study identified a positive correlation between TCRP1 expression and primary resistance to DDP and L-OHP in lung cancer cells. In addition, it was observed that cells treated with nuclear factor (NF)-κB inhibitor BAY 11-7082 displayed increased sensitivity to DDP and L-OHP. The results of the present study suggested that TCRP1 may be associated with resistance to DDP and L-OHP in lung and ovarian cancer cells, and the Akt/NF-κB signaling pathway may be involved in the functioning of TCRP1. These findings identify TCRP1 as a potential predictor of platinum resistance in the treatment of lung and ovarian cancer.

Keywords: lung cancer; nuclear factor-κB; ovarian cancer; platinum sensitivity; tongue cancer resistance-associated protein 1

References

  1. Stem Cells. 2014 Jul;32(7):1943-55 - PubMed
  2. FEBS Lett. 2011 Mar 23;585(6):881-7 - PubMed
  3. Am J Physiol Cell Physiol. 2000 Mar;278(3):C451-62 - PubMed
  4. Oncogene. 2003 Jan 9;22(1):90-7 - PubMed
  5. Lung Cancer. 2013 Jul;81(1):102-8 - PubMed
  6. Mol Cancer Ther. 2002 Jan;1(3):227-35 - PubMed
  7. Protein Expr Purif. 2012 Apr;82(2):360-7 - PubMed
  8. PLoS One. 2012;7(12):e51413 - PubMed
  9. Oncogene. 2003 May 22;22(21):3243-51 - PubMed
  10. Neoplasia. 2011 Nov;13(11):1069-80 - PubMed
  11. Mol Cell Biochem. 2015 Jan;398(1-2):175-83 - PubMed
  12. BMC Cancer. 2012 Mar 19;12 :91 - PubMed
  13. Oncogene. 2012 Apr 12;31(15):1869-83 - PubMed
  14. Mol Cancer Ther. 2006 Sep;5(9):2149-57 - PubMed
  15. Int J Gynecol Cancer. 2009 Jul;19(5):820-5 - PubMed
  16. Gastric Cancer. 2011 Mar;14(1):50-5 - PubMed
  17. J Exp Clin Cancer Res. 2013 Apr 30;32:25 - PubMed
  18. Clin Chem. 2014 Oct;60(10):1282-9 - PubMed
  19. Oncol Rep. 2014 Sep;32(3):1003-12 - PubMed
  20. Nat Rev Clin Oncol. 2016 Apr;13(4):255-61 - PubMed
  21. Int J Oncol. 2008 May;32(5):1133-7 - PubMed
  22. Cancer Chemother Pharmacol. 2014 Oct;74(4):681-90 - PubMed
  23. Gynecol Oncol. 2013 Sep;130(3):426-30 - PubMed
  24. Int J Cancer. 2010 Jan 15;126(2):437-49 - PubMed
  25. FEBS J. 2010 Nov;277(21):4506-18 - PubMed
  26. Mol Cell Biochem. 2011 Nov;357(1-2):107-13 - PubMed
  27. Cancers (Basel). 2011 Mar 15;3(1):1351-71 - PubMed
  28. Mol Cell Biol. 2007 Jun;27(11):3920-35 - PubMed
  29. Int J Clin Exp Pathol. 2015 Nov 01;8(11):15245-9 - PubMed
  30. Oncol Rep. 2014 Jan;31(1):391-6 - PubMed
  31. Pharmacol Rev. 2012 Jul;64(3):706-21 - PubMed
  32. J Biol Chem. 2013 Oct 18;288(42):30399-410 - PubMed
  33. Oncogene. 2003 Oct 20;22(47):7265-79 - PubMed
  34. Immunol Rev. 2013 Mar;252(1):41-51 - PubMed

Publication Types